Treosulfan Pharmacokinetics in Children Undergoing Allogeneic HSCT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

61 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-03-31

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Every year around 70 children affected by cancer or life-threatening genetic diseases undergo haematopoietic cell transplantation (HCT) within the Blood and Marrow Transplant (BMT) unit at Great Ormond Street Hospital (GOSH).

One of the main goals of the BMT unit over the last decade has been to reduce the morbidity and mortality related to HCT, and the group has become a world-leader in pioneering less toxic transplants.

Fixed high doses of chemotherapy drugs are generally used to prepare children for HCT but several studies have shown a correlation between the concentration of these drugs achieved in the patient's blood, and the success or failure of the HCT procedure.

Recently a new drug, Treosulfan, has become available for use in patients undergoing HCT, and GOSH has pioneered its introduction in children undergoing HCT. With promising early results, Treosulfan has become the pre-HCT drug of choice, however, very little is currently known about how the drug is metabolised and cleared from the body, particularly in children.

The investigators therefore plan to investigate the pharmacokinetic (PK) profile of Treosulfan in children undergoing HCT at GOSH and define which parameters affect its metabolism and clearance, and what blood levels are associated with a favourable outcome (graft take without toxicity) or a poor result (graft rejection and/or toxicity).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treosulfan Therapeutic Drug Monitoring in Pediatric Hematopoietic Stem Cell Transplant Recipients

NCT06861257

Pediatric Hematopoietic Stem Cell Transplantation Malignant Disorders Non-malignant Disorders

RECRUITING

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

NCT00253513

Leukemia Myelodysplastic Syndromes

COMPLETED PHASE1/PHASE2

Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

NCT01772953

Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)

COMPLETED PHASE2

Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome

NCT07316595

HSCT Nijmegen Breakage Syndrome Treosulfan Based Conditioning

NOT_YET_RECRUITING PHASE2

ALL-SCT BFM International- HSCT in Children and Adolescents With ALL

NCT01423500

Lymphoblastic Leukemia, Acute, Childhood;

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allogeneic Haematopoietic Stem Cell Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treosulfan PK

Children with indication to HSCT receiving Treosulfan

Treosulfan

Intervention Type DRUG

Treosulfan will be administered over 3 days prior to HSCT at the following dose: 10 g/m2 (children aged \< 3months) or 12 g/m2 (children aged 3/12 months) or 14 g/m2 (children aged \> 12 months)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treosulfan

Treosulfan will be administered over 3 days prior to HSCT at the following dose: 10 g/m2 (children aged \< 3months) or 12 g/m2 (children aged 3/12 months) or 14 g/m2 (children aged \> 12 months)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. age ≥ 28 days and ≤ 18 years old;
2. Karnofsky Performance Status ≥ 50 or Lansky Performance Status ≥ 30;
3. provide signed, written informed consent from parent or guardian;
4. be able to comply with study procedures and follow-up examinations;
5. have adequate organ function (as indicated by Table 1, page 27), within 14 days prior enrollment;
6. negative pregnancy test in post-pubertal female patients.

Exclusion Criteria

1. patients aged \< 28 days and \> 18 years old;
2. patients with compromised organ function\*;
3. patients with any other severe concurrent disease, which, in the judgment of the Investigator, would make the patient inappropriate for entry into this study;
4. known hypersensitivity to Treosulfan or Fludarabine;
5. pregnancy/lactation.

Minimum Eligible Age

28 Days

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No